The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already-approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to investigate the mechanism of action of
mebendazole, an antihelminthic drug, currently repurposed in the treatment of
brain tumors. First, we confirmed that
mebendazole decreased the viability of
glioblastoma cells in vitro (IC50 values ranging from 288 nm to 2.1 µm). Our in silico approach unveiled 21 putative molecular targets for
mebendazole, including 12
proteins significantly upregulated at the gene level in
glioblastoma as compared to normal brain tissue (fold change > 1.5; P < 0.0001). Validation experiments were performed on three major
kinases involved in
cancer biology: ABL1, MAPK1/ERK2, and
MAPK14/p38α.
Mebendazole could inhibit the activity of these
kinases in vitro in a dose-dependent manner, with a high potency against
MAPK14 (IC50 = 104 ± 46 nm). Its direct binding to
MAPK14 was further validated in vitro, and inhibition of
MAPK14 kinase activity was confirmed in live
glioblastoma cells. Consistent with biophysical data, molecular modeling suggested that
mebendazole was able to bind to the catalytic site of
MAPK14. Finally, gene silencing demonstrated that
MAPK14 is involved in
glioblastoma tumor spheroid growth and response to
mebendazole treatment. This study thus highlighted the role of
MAPK14 in the anticancer mechanism of action of
mebendazole and provides further rationale for the pharmacological targeting of
MAPK14 in
brain tumors. It also opens new avenues for the development of novel
MAPK14/p38α inhibitors to treat human diseases.